So for the FDA, the time of approval as the endpoint for market authorization is appropriate. In Europe, the EMA's process involves one more step, creating an intermediate time point that seems to ...

John Stewart, National Director for Specialised Commissioning, said: “Since 2019, thousands of people with cystic fibrosis have been able to benefit from licensed treatments – firstly Orkambi® and ...